/BEAM
BEAM Stock - Beam Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$26.57+1.53%
+$0.40 (+1.53%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.89
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.31
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+43.0%upside
Target: $38.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BEAM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.30 – $26.84
TARGET (TP)$38.00
STOP LOSS$24.44
RISK/REWARD1:5.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.22
52W High$35.25
52W Low$13.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $63.52M | $377.71M | $60.92M | $51.84M | $24,000 |
| Gross Profit | $-304,043,000 | $377.71M | $-250,674,000 | $-180,290,000 | $-103,155,000 |
| Gross Margin | -478.7% | 100.0% | -411.5% | -347.8% | -429812.5% |
| Operating Income | $-415,568,000 | $-176,485,000 | $-338,479,000 | $-392,465,000 | $-132,759,999 |
| Net Income | $-376,742,000 | $-132,527,000 | $-289,088,000 | $-370,638,000 | $-194,592,000 |
| Net Margin | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% |
| EPS | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-5.49 |
Company Overview
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
67%
Hold / Neutral
4
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
8 Bullish4 Neutral/Bearish
Price Targets
$46
Average Target
↑ 74.9% Upside
Now
$20
Low
$46
Average
$80
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 9th 2025 | Jefferies | Initiation | Buy | $41 |
| March 28th 2025 | BofA Securities | Upgrade | Buy | $42 |
| March 10th 2025 | Scotiabank | Upgrade | Sector Outperform | $40 |
| January 29th 2025 | Cantor Fitzgerald | Upgrade | Overweight | - |
| November 6th 2024 | Leerink Partners | Upgrade | Outperform | $39← $27 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| July 23rd 2024 | H.C. Wainwright | Initiation | Buy | $80 |
| January 29th 2024 | JP Morgan | Upgrade | Overweight | $40← $38 |
| December 15th 2023 | BofA Securities | Downgrade | Neutral | $35 |
| December 8th 2023 | Jefferies | Downgrade | Hold | $30← $75 |
| October 20th 2023 | Cantor Fitzgerald | Downgrade | Neutral | - |
| October 20th 2023 | Leerink Partners | Downgrade | Market Perform | $20← $75 |
| March 21st 2023 | Bernstein | Initiation | Market Perform | $37 |
| February 1st 2023 | Cantor Fitzgerald | Initiation | Overweight | $62 |
| December 20th 2022 | BMO Capital Markets | Upgrade | Outperform | $66← $61 |
Earnings History & Surprises
BEAMBeat Rate
72%
Last 18 quarters
Avg Surprise
+20.3%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-1.10
Q4 2025
EPS Surprise History
Q1 24
+271.3%
$1.73vs$-1.01
Q2 24
+16.6%
$-1.21vs$-1.45
Q3 24
+1.8%
$-1.11vs$-1.13
Q4 24
-3.5%
$-1.17vs$-1.13
Q1 25
+12.8%
$-1.09vs$-1.25
Q2 25
-11.7%
$-1.24vs$-1.11
Q3 25
+3.8%
$-1.00vs$-1.04
Q4 25
-12.2%
$-1.10vs$-0.98
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-1.13 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.98 | $-1.10 | -12.2% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-1.04 | $-1.00 | +3.8% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.11 | $-1.24 | -11.7% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-1.25 | $-1.09 | +12.8% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-1.13 | $-1.17 | -3.5% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-1.13 | $-1.11 | +1.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-1.45 | $-1.21 | +16.6% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-1.01 | $1.73 | +271.3% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-1.37 | $-1.22 | +10.9% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.38 | $-1.08 | +21.7% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-1.36 | $-1.33 | +2.2% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.32 | $-0.54 | +59.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-1.30 | $-1.56 | -20.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-1.08 | $-1.02 | +5.6% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-1.10 | $-1.01 | +8.2% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-1.02 | $-0.85 | +16.7% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.78 | $-0.42 | +46.2% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.58 | $-0.95 | -63.8% | ✗ MISS |
Latest News
Reported Saturday, Beam Therapeutics Highlights Risto-Cel Durable Hemoglobin F Induction >60% And Hemoglobin S Reduction
📈 PositiveBenzinga•Dec 8, 2025, 09:27 AM
Beam Therapeutics shares are trading higher after Evercore ISI initiated coverage on the stock with an Outperform rating and announced a $35 price target.
📈 PositiveBenzinga•Nov 24, 2025, 04:01 PM
Evercore ISI Group Initiates Coverage On Beam Therapeutics with Outperform Rating, Announces Price Target of $35
📈 PositiveBenzinga•Nov 24, 2025, 02:56 PM
Beam Therapeutics Q3 EPS $(1.10) Misses $(1.05) Estimate, Sales $9.698M Miss $12.368M Estimate
📉 NegativeBenzinga•Nov 4, 2025, 12:09 PM
Beam Therapeutics To Present Updated Safety, Efficacy Data From BEACON Phase 1/2 Clinical Study Of BEAM-101 In Sickle Cell Disease At American Society Of Hematology
➖ NeutralBenzinga•Nov 3, 2025, 02:16 PM
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
📈 PositiveBenzinga•Oct 10, 2025, 11:02 AM
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 11:41 AM
Frequently Asked Questions about BEAM
What is BEAM's current stock price?
Beam Therapeutics Inc. (BEAM) is currently trading at $26.57 per share. The stock has moved +1.53% today.
What is the analyst price target for BEAM?
The average analyst price target for BEAM is $38.00, based on 1 analyst.
What sector is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BEAM's market cap?
Beam Therapeutics Inc. has a market capitalization of $2.70 billion, making it a mid-cap company.
Does BEAM pay dividends?
No, Beam Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
Explore stocks similar to BEAM for comparison